WorldFuture and humanity

Sanofi Granted Sciwind Biosciences Rights to Sanofi's GIP Receptor Agonist Program
receptor Agonist

Sanofi Granted Sciwind Biosciences Rights to Sanofi's GIP Receptor Agonist Program

HANGZHOU, China and SAN FRANCISCO/PRNewswire/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced that it has signed a global, exclusive license agreement with Sanofi to develop and commercialize Sanofi’s long-lasting glucose-dependent insulinotropic polypeptide (GIP) receptor agonists,
1 min read